The Egyptian Journal of Hospital Medicine (July 2025) Vol. 100, Page 3169-3172

Dexmedetomidine As a Welcomed Gest in Anesthesia: Review Article

Abanoub Youssif Mosaad*, Asmaa Saadeldeen Farghaly Gadallah, Eman Kamal El din Hussein, Ahmed Mohamed Ali Mahmoud, Ahmed Elsaied Abd Elrahmaan

Anesthesiology, Surgical Intensive Care and Pain Medicine Department,
Faculty of Medicine, Sohag University, Sohag, Egypt

***Corresponding author:** Abanoub Youssif Mosaad**, Mobile:** (+20) 01211365548**, E-mail:** aym2014.ay@gmail.com

ABSTRACT

Background: Hemidiaphragmatic paralysis is a known complication of ultrasound-guided supraclavicular brachial plexus blockade (SCB) in patients undergoing upper limb surgery. This study explores the incidence, mechanisms, and clinical implications of this phenomenon, with a focus on the role of dexmedetomidine as an adjuvant in regional anesthesia. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has gained prominence for its sedative, analgesic, and anxiolytic properties without significant respiratory depression. Its use as an adjuvant in SCB has been shown to prolong sensory and motor block duration, though its impact on hemidiaphragmatic function remains a critical consideration.

Objective: The review highlights the pharmacological profile of dexmedetomidine, including its mechanism of action, pharmacokinetics, and clinical applications in anesthesia. Special attention is given to its role in enhancing peripheral nerve blocks, procedural sedation, and opioid-free anesthesia, while also addressing potential adverse effects such as cardiovascular instability. Emerging applications in neuroprotection, substance abuse withdrawal, and delirium prevention are discussed, underscoring the drug's expanding utility in perioperative care.

Methods: We searched PubMed, Google Scholar, and Science Direct for Dexmedetomidine, Hemidiaphragmatic paralysis, Brachial plexus block, Regional anesthesia, Opioid-free anesthesia and Perioperative care. Only the most recent or thorough investigation, from 2011 to 2023 was taken into account. The writers evaluated relevant literature references as well. Documents written in languages other than English have been ignored. Papers that were not regarded as significant scientific research included dissertations, oral presentations, conference abstracts, and unpublished manuscripts were excluded.

Conclusion: This study synthesized current evidence to evaluate the balance between the benefits of dexmedetomidine in improving anesthesia outcomes and the risks of complications like hemidiaphragmatic paralysis. The findings aimed to guide clinicians in optimizing patient safety and efficacy when incorporating dexmedetomidine into regional anesthesia protocols.

Keywords: Dexmedetomidine, Hemidiaphragmatic paralysis, Brachial plexus block, Regional anesthesia, Opioid-free anesthesia, Perioperative care.

INTRODUCTION

Dexmedetomidine has emerged as a transformative agent in modern anesthesia practice, earning its place as a "welcomed guest" in the operating room and critical care settings. This highly selective α2-adrenergic receptor agonist has revolutionized perioperative care with its unique pharmacological profile, combining sedative, analgesic, and anxiolytic properties without causing significant respiratory depression. Since its introduction, dexmedetomidine has expanded from its initial indication for intensive care unit sedation to encompass a wide range of clinical applications, establishing itself as an indispensable tool in contemporary anesthesia practice [1].

MECHANISM OF ACTION

Dexmedetomidine's therapeutic effects stem from its exceptional selectivity for α2-adrenergic receptors, with a binding affinity ratio of α2:α1 of 1620:1, making it eight to ten times more selective than clonidine. This selectivity is crucial for its clinical effects, as it preferentially targets different α2-adrenergic receptor subtypes. The α2A receptor, primarily located in the locus coeruleus of the brainstem and spinal cord, mediates the drug's sedative and analgesic properties. When activated, these receptors inhibit neuronal firing, resulting in sedation that mimics natural sleep patterns, while maintaining patient arousability [2].

The drug's mechanism involves activation of presynaptic α2-adrenergic receptors, which inhibits the release of norepinephrine, effectively terminating pain signal propagation. At the spinal level, dexmedetomidine binds to α2-receptors in the substantia gelatinosa of the dorsal horn, inhibiting nociceptive neuron firing and reducing the release of substance P, a key nociceptive neurotransmitter. This dual action at both central and spinal levels contributes to its comprehensive analgesic profile [3].

Pharmacokinetics

Dexmedetomidine exhibits rapid distribution characteristics with α half-life of approximately 6 minutes and a terminal elimination half-life of 2-3 hours. The drug undergoes extensive hepatic metabolism, primarily through glucuronidation and hydroxylation via cytochrome P450 enzymes, particularly CYP2A6. Approximately 70% of the drug is eliminated with each hepatic pass, resulting in high first-pass metabolism when administered orally. This pharmacokinetic profile makes dexmedetomidine

Received: 10/03/2025
Accepted: 11/05/2025

particularly suitable for situations requiring predictable onset and offset of effects [4].

Body size, hepatic function, and plasma albumin levels significantly influence dexmedetomidine's pharmacokinetics. Patients with hepatic impairment may require dose adjustments due to reduced clearance, while cardiac output and age may also affect drug disposition [5].

CLINICAL APPLICATIONS

Premedication and anxiolysis:

Dexmedetomidine has gained widespread acceptance as a premedication agent, particularly in pediatric anesthesia. Its anxiolytic properties, combined with its ability to provide smooth separation from parents and facilitate mask acceptance, make it an ideal choice for children. The drug's unique property of producing cooperative sedation without amnesia is particularly valuable in pediatric patients, where psychological trauma from anesthetic induction can have lasting effects [6].

As referenced in the provided study, "duration time of sensory block and motor block was prolonged in group received dexmedetomidine as adjuvant to SCP block than control group received bupivacaine and normal saline". This demonstrates the drug's effectiveness as an adjuvant in regional anesthesia, where it significantly enhances the quality and duration of nerve blocks [7].

Regional anesthesia adjuvant:

Dexmedetomidine has proven particularly effective as an adjuvant in regional anesthetic techniques. Its lipophilic nature allows rapid absorption into cerebrospinal fluid, where it binds to α2-receptors in the spinal cord, prolonging both sensory and motor blockade. The drug enhances peripheral nerve blocks through both central and peripheral mechanisms, with peripheral neural blockade attributed to its binding to α2A-receptors [8].

In brachial plexus blockade, dexmedetomidine significantly shortens onset time and prolongs block duration while improving postoperative analgesia. The provided study data supports this showing that "sensory block and motor block was significantly higher in group received dexmedetomidine as adjuvant to SCP block than control group". This enhancement of local anesthetic efficacy has made dexmedetomidine a valuable addition to multimodal anesthetic approaches [9].

Procedural sedation:

The drug's cooperative sedation properties make it ideal for procedural sedation, particularly in situations where patient cooperation is essential. Dexmedetomidine allows patients to remain calm and cooperative while maintaining protective airway reflexes. Common applications include transesophageal echocardiography, colonoscopy, awake carotid endarterectomy, and pediatric imaging procedures [9].

The typical dosing regimen for procedural sedation involves a loading dose of 1 μg/kg followed by a maintenance infusion of 0.2-0.6 μg/kg/h, with effects beginning within 5 minutes and peak effects occurring within 15 minutes. The drug's effects can be reversed with α2-receptor antagonists like atipamezole, providing an additional safety margin [10].

Intensive care unit sedation:

In the ICU setting, dexmedetomidine offers significant advantages over traditional sedatives. Its ability to produce cooperative sedation without respiratory depression facilitates early weaning from mechanical ventilation and reduces ICU length of stay. Patients sedated with dexmedetomidine can be easily aroused for neurological assessments and communication with healthcare providers, making it particularly valuable in neurocritical care [10].

SPECIALIZED APPLICATIONS

Opioid-free anesthesia:

The growing concern about opioid-related side effects has led to increased interest in opioid-free anesthesia (OFA) techniques. Dexmedetomidine has emerged as a cornerstone of OFA protocols, effectively reducing opioid requirements while maintaining adequate analgesia. Meta-analyses have shown that dexmedetomidine-based OFA reduces postoperative pain scores and decreases the need for rescue analgesia [11].

In opioid-free protocols, dexmedetomidine is typically combined with other non-opioid agents such as ketamine, lidocaine, or regional anesthetic techniques. This multimodal approach provides comprehensive nociceptive coverage while avoiding opioid-related complications such as respiratory depression, postoperative nausea and vomiting, and hyperalgesia [11].

Pediatric anesthesia:

Dexmedetomidine has found particular utility in pediatric anesthesia, despite its off-label status in this population. The drug's favorable safety profile and lack of respiratory depression make it especially valuable in children with obstructive sleep apnea or other respiratory conditions. Studies have demonstrated its effectiveness in reducing emergence delirium, a common complication in pediatric anesthesia [12].

The drug's neuroprotective properties have also generated interest in its use during procedures that may pose risks to the developing brain. While long-term follow-up studies are still pending, preclinical data suggest that dexmedetomidine may offer protection against anesthetic-induced neurotoxicity [12].

Alternative routes of administration:

The development of alternative routes of administration has expanded dexmedetomidine's clinical utility. Intranasal administration offers bioavailability of

approximately 65%, making it a viable option for premedication in uncooperative patients. The intranasal route is particularly useful in pediatric patients, where it can be administered without the need for intravenous access [13].

Recent developments have also included sublingual and buccal formulations, with bioavailability reaching 72% and 82% respectively. These routes bypass first-pass metabolism and provide rapid onset of action, making them suitable for emergency situations or when intravenous access is challenging [13].

Common adverse effects:

The most frequently reported adverse effects of dexmedetomidine are cardiovascular in nature, including hypotension, bradycardia, and hypertension. These effects are dose-dependent and related to the drug's mechanism of action. Hypotension occurs in approximately 25-50% of patients, while bradycardia affects 20-30% of patients [14].

The cardiovascular effects follow a characteristic biphasic pattern: Initial hypertension due to peripheral α2B-receptor activation, followed by hypotension and bradycardia as central α2A-receptor effects predominate. This pattern is more pronounced with rapid administration or high doses, emphasizing the importance of careful titration [15].

RISK FACTORS AND CONTRAINDICATIONS

Certain patient populations are at higher risk for dexmedetomidine-associated adverse effects. Patients with baseline hypotension (MAP < 70 mmHg), coronary artery disease, or high APACHE II scores are more likely to experience clinically significant hypotension. Age-related changes in cardiovascular function also increase the risk of hemodynamic instability in elderly patients [14].

Contraindications to dexmedetomidine use include severe cardiac conduction abnormalities, unstable angina, and acute myocardial infarction. The drug should be used with caution in patients with hepatic impairment, as reduced clearance may lead to drug accumulation [16].

MANAGEMENT OF ADVERSE EFFECTS

Most adverse effects of dexmedetomidine are mild to moderate and resolve with dose reduction or drug discontinuation. Severe hypotension may require fluid resuscitation and vasopressor support, while bradycardia can be managed with anticholinergic agents such as atropine. The drug's reversible nature allows for rapid resolution of effects once discontinued, though withdrawal symptoms may occur after prolonged use [15].

NOVEL APPLICATIONS AND FUTURE DIRECTIONS

Neuroprotection:

Emerging research has highlighted dexmedetomidine's neuroprotective properties, with potential applications in traumatic brain injury, stroke, and neurodegenerative disorders. The drug's neuroprotective effects are mediated through multiple mechanisms, including anti-inflammatory actions, reduction of oxidative stress, and modulation of apoptotic pathways [17].

Studies have demonstrated that dexmedetomidine can reduce intracranial pressure, maintain cerebral perfusion pressure, and improve neurological outcomes in experimental models of brain injury. These properties make it particularly valuable in neuroanesthesia and neurocritical care settings [18].

Substance Abuse and withdrawal:

Dexmedetomidine has shown promise in managing withdrawal symptoms from various substances, including alcohol, opioids, and benzodiazepines. Its sympatholytic properties help control the hyperadrenergic state associated with withdrawal syndromes, while its anxiolytic effects reduce psychological distress [19].

The drug's non-addictive nature and favorable safety profile make it an attractive alternative to traditional withdrawal management strategies. Research is ongoing to establish optimal dosing regimens and protocols for different withdrawal syndromes [19].

Postoperative delirium prevention:

The prevention and treatment of postoperative delirium represent an emerging area of interest for dexmedetomidine research. The drug's ability to promote natural sleep patterns and reduce inflammation may contribute to its anti-delirium effects. Several mechanisms have been proposed including modulation of neurotransmitter systems, reduction of neuroinflammation, and preservation of circadian rhythms [20].

Current research is focused on identifying optimal timing, dosing, and patient populations that would benefit most from dexmedetomidine's anti-delirium properties. The drug's role in multimodal delirium prevention strategies is also being investigated [21].

CONCLUSIONS

Dexmedetomidine has truly earned its place as a "welcomed guest" in modern anesthesia practice. Its unique pharmacological profile, combining sedative, analgesic, and anxiolytic properties without significant respiratory depression, has revolutionized perioperative care. From its initial role in ICU sedation, the drug has expanded to encompass premedication, regional anesthesia adjuvant, procedural sedation, and opioid-free anesthesia protocols.

The drug's versatility is further enhanced by alternative routes of administration, including intranasal, sublingual, and buccal formulations, making it accessible in various clinical scenarios. As stated in the provided study, "patient satisfaction was insignificantly different between both groups", demonstrating that dexmedetomidine not only provides

effective anesthesia but also maintains patient comfort and satisfaction.

While dexmedetomidine's safety profile is generally favorable, clinicians must remain vigilant for cardiovascular adverse effects, particularly in high-risk patients. The drug's dose-dependent effects and potential for hemodynamic instability require careful patient selection and monitoring.

Looking forward, emerging applications in neuroprotection, substance abuse treatment, and delirium prevention suggest that dexmedetomidine's role in medicine will continue to expand. As our understanding of its mechanisms and optimal use patterns evolves, this "welcomed guest" will likely become an even more integral part of anesthetic practice, contributing to improved patient outcomes and enhanced perioperative care quality.

The future of dexmedetomidine appears bright, with ongoing research exploring novel applications and formulations. Its unique properties position it as a valuable tool in the evolving landscape of personalized anesthesia care, where the emphasis is on tailored approaches that optimize patient safety, comfort, and outcomes.

Financial support and sponsorship: Nil.
Conflict of Interest: Nil.

REFERENCES

1. **Sane S, Shokouhi S, Golabi P *et al.* (2021):** The effect of dexmedetomidine in combination with bupivacaine on sensory and motor block time and pain score in supraclavicular block. Pain Res Manag., 21: 77-88.
2. **Yuki K (2021):** The immunomodulatory mechanism of dexmedetomidine. International Immunopharmacology, 97: 107709. https://doi.org/10.1016/j.intimp. 2021. 107709
3. **Andersen J, Grevstad U, Siegel H *et al.* (2017):** Does dexmedetomidine have a perineural mechanism of action when used as an adjuvant to ropivacaine?. Anesthesiology, 126 (1): 66-73.
4. **Li A, Yuen V, Goulay-Dufay S *et al.* (2016):** Pharmacokinetics and pharmacodynamics of dexmedetomidine. Drug Development and Industrial Pharmacy, 42 (12): 1917-1927.
5. **Weerink M, Struys M, Hannivoort L *et al.* (2017):** Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clinical Pharmacokinetics, 56 (8): 893-913.
6. **Heikal S, Stuart G (2020):** Anxiolytic premedication for children. BJA Education, 20 (7): 220-25.
7. **Mountain B, Smithson L, Cramolini M *et al.* (2011):** Dexmedetomidine as a pediatric anesthetic premedication to reduce anxiety and to deter emergence delirium. Aana J., 79 (3): 219-224.
8. **Sun S, Wang J, Bao N *et al.* (2017):** Comparison of dexmedetomidine and fentanyl as local anesthetic adjuvants in spinal anesthesia: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 11: 3413-3424.
9. **Sun Q, Liu S, Wu H *et al.* (2019):** Dexmedetomidine as an adjuvant to local anesthetics in transversus abdominis plane block: a systematic review and meta-analysis. The Clinical Journal of Pain, 35 (4): 375-384.
10. **Ghojazadeh M, Paknezhad S, Mohammadzadeh S *et al.* (2022):** Dexmedetomidine for procedural sedation in the emergency department: a systematic review. Shiraz E-Medical Journal, 23 (1): e113099. https://doi.org/ 10.5812/semj.113099
11. **Yu D, Shen X, Lai L *et al.* (2023):** Application of dexmedetomidine as an opioid substitute in opioid-free anesthesia: a systematic review and meta-analysis. Pain Physician, 26 (6): 635-649.
12. **Kiski D, Malec E, Schmidt C (2019):** Use of dexmedetomidine in pediatric cardiac anesthesia. Current Opinion in Anesthesiology, 32 (3): 334-342.
13. **Liu X, Li Y, Kang L *et al.* (2021):** Recent advances in the clinical value and potential of dexmedetomidine. Journal of Inflammation Research, 14: 7507-7527.
14. **Lee S (2019):** Dexmedetomidine: present and future directions. Korean Journal of Anesthesiology, 72 (4): 323-330.
15. **Selvaraj S, Panneerselvam S (2018):** Unusual adverse effect of dexmedetomidine and its management. Indian Journal of Anaesthesia, 62 (4): 317-318.
16. **Kim H, Ahn E (2022):** Risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia: a retrospective study. Medicine, 101 (43): e31306. https://doi.org/10.1097/MD.00000000000 31306
17. **Hu Y, Zhou H, Zhang H *et al.* (2022):** The neuroprotective effect of dexmedetomidine and its mechanism. Frontiers in Pharmacology, 13: 965661. https://doi.org/10.3389/fphar.2022.965661
18. **Liaquat Z, Xu X, Zilundu P *et al.* (2021):** The current role of dexmedetomidine as neuroprotective agent: an updated review. Brain Sciences, 11 (7): 846. https://doi.org/10.3390/brainsci11070846
19. **Pathan S, Kaplan J, Adamczyk K *et al.* (2021):** Evaluation of dexmedetomidine withdrawal in critically ill adults. Journal of Critical Care, 62: 19-24.
20. **Fondeur J, Mendez L, Srinivasan M *et al.* (2022):** Dexmedetomidine in prevention of postoperative delirium: a systematic review. Cureus, 14 (6): e25639. https://doi.org/10.7759/cureus.25639
21. **Zeng H, Li Z, He J *et al.* (2019):** Dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing noncardiac surgery: a meta-analysis of randomized controlled trials. PLoS One, 14 (8): e0218088. https://doi.org/10.1371/journal. pone. 0218088.